Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$29.79M+656.49%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert N. Fried
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 117
- Beta
- 2.09
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 5.92
Financials
Revenue
$29.79M+656.5%Net Income
$963.0KEBITDA
$1.17MFree Cash Flow
$2.68MEPS (diluted)
$0.01Shares Outstanding (diluted)
82.50M+117.9%Operating Expenses
$18.61MCash & Debt
$66.74MReturn of Capital
$2.77MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $129.42M | $17.38M | $0.22 |
| 2024 | $99.60M | $8.55M | $0.11 |
| 2023 | $83.57M | $-4.94M | $-0.07 |
| 2022 | $72.05M | $-16.54M | $-0.24 |
| 2021 | $67.45M | $-27.13M | $-0.40 |
| 2020 | $59.26M | $-19.93M | $-0.33 |
| 2019 | $46.29M | $-32.15M | $-0.56 |
| 2018 | $31.56M | $-33.32M | $-0.61 |
| 2017 | $21.20M | $-11.38M | $-0.26 |
| 2016 | $21.66M | $-2.93M | $-0.08 |
| 2015 | $17.88M | $-2.77M | $-0.08 |
| 2014 | $15.31M | $-5.39M | $-0.15 |
| 2013 | $10.16M | $-4.42M | $-0.13 |
| 2012 | $11.61M | $-11.66M | $-0.39 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.32
- Implied price
- $9.35
- Return from $2.79
- 27.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.65 — today's price is already 40.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| -2.0% | 8.4% | 12.2% | 15.6% | 18.6% | 21.4% |
| 3.0% | 13.9% | 17.9% | 21.5% | 24.7% | 27.5% |
| 8.0% | 19.4% | 23.6% | 27.4% | 30.7% | 33.7% |
| 13.0% | 24.9% | 29.4% | 33.3% | 36.8% | 39.9% |
| 18.0% | 30.5% | 35.1% | 39.2% | 42.8% | 46.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70-12.50%Social Signal Score
Mentions (4)
- Newsbusinesswire.com·19d ago·Negative
…gages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BioPharma--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the adv…
View source ↗ - Newsbusinesswire.com·26d ago·Neutral
Niagen Bioscience to Present at Canaccord Genuity's Well Summit LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's Well Summit, taking place from September 28 to 30, 2026, in New York. Mr. Fried is scheduled t…
View source ↗ - Newsbusinesswire.com·34d ago·Positive
Niagen Bioscience to Present at Longevity Investors Conference LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Longevity Investors Conference, taking place from September 14 to 17, 2026, in Gstaad, Switzerland.Niagen Bioscience CEO, Rob Fried, will participate in the Longevity Goes Ma…
View source ↗ - Newsbusinesswire.com·47d ago·Negative
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD-boosting supplement in the United States†, is now available at GNC and Sam's Club retail locations and online at www.gnc.com and www.samsclub.com. “Expand…
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.01 per share
Typical surprise +100.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.01 vs $0.01beat
- Wed, May 6$0.07 vs $0.06beat
- Wed, Mar 4$0.03 vs $0.02beat
- Tue, Nov 4$0.05 vs $0.01beat
- Wed, Aug 6$0.04 vs $0.02beat
- Wed, May 7$0.04 vs $0.02beat
Estimates and results for NAGE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NAGE officers and directors.
- Bought
- $46k
- Sold
- —
2 trades
0 trades
- Pamir Ozanbought
- Pamir Ozanbought
24 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NAGE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.